Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab.
Joshua RichterVamshi Ruthwik AnupindiJason YeawSuneel KudaravalliStojan ZavisicDrishti ShahPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)
RRMM patients showed a high frequency of AEs, low OS, and a substantial economic burden suggesting need for effective treatment options.